MarketPulse

weight loss market

3 articles
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Pfizer and Novo Nordisk: Undervalued Pharma Giants Poised for Rebounds

Pfizer and Novo Nordisk trade at 9x-10.5x forward earnings with deep pipelines offering long-term value potential despite recent underperformance.
PFELLYNVOclinical trialshealthcare stocks
The Motley FoolThe Motley Fool··Adria Cimino

Viking Therapeutics Positioned for Market Expansion as Obesity Drug Sector Scales

Viking Therapeutics poised for growth as obesity drug market expands to $100 billion by decade's end. VK2735's Phase 3 success could establish the company as a key competitor.
LLYNVOVKTXbiotechPhase 3 trial
The Motley FoolThe Motley Fool··Prosper Junior Bakiny

Oral Weight-Loss Drug Expands Market Rather Than Cannibalizing Sales

Oral weight-loss drugs expand the market rather than cannibalizing injectables, attracting new patients. However, Novo Nordisk expects 2026 revenue headwinds from competition and pricing pressures.
LLYNVOGLP-1 drugspharmaceutical competition